SCHEMBL6273166

SCHEMBL6273166

Cc1c(C)c2cc(CCCl)ccc2[nH]c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.46
HTT P42858 2/20 0.46
HSD17B10 Q99714 2/20 0.46
TSHR P16473 1/20 0.46
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
RECQL P46063 1/20 0.42
PARP1 P09874 3/20 0.38
GRIN2D O15399 2/20 0.38
GRIN3B O60391 2/20 0.38
GRIN1 Q05586 2/20 0.38
GRIN2A Q12879 2/20 0.38
GRIN2B Q13224 2/20 0.38
GRIN2C Q14957 2/20 0.38
GRIN3A Q8TCU5 2/20 0.38
RAB9A P51151 1/20 0.38
TBXAS1 P24557 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7028562 0.78 CA12 (0.47) MAPTHSD17B10KDM4EALDH1A1HPGD
SCHEMBL28092175 0.73 MAPT (0.44) MAPTHTTHSD17B10KDM4EALDH1A1
SCHEMBL6751107 0.73 KDM4E (0.50) MAPTHTTHSD17B10TSHRKDM4E
SCHEMBL6910223 0.69 GAA (0.59) MAPTALDH1A1GAAGRIN2DGRIN3B
SCHEMBL17080919 0.69 HTR1A (0.51) MAPT
SCHEMBL23674337 0.69 HSD17B10 (0.55) MAPTHTTHSD17B10TSHRKDM4E
SCHEMBL2056334 0.69 DAO (0.51) MAPTHTTHSD17B10TSHRKDM4E
SCHEMBL6554308 0.69 PARP1 (0.55) HSD17B10KDM4EALDH1A1PARP1MEN1
SCHEMBL7027027 0.68 PARP1 (0.46) KDM4EALDH1A1HPGDGAAPARP1
SCHEMBL11970184 0.67 HCRTR1 (0.49) MAPTHTTHSD17B10TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546143-A1 HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA Warner-Lambert Company LLC (US) 2005-06-29 EP disclosed
US-20040138230-A1 Heterocyclic substituted piperazines for the treatment of schizophrenia ANDREANA TONJA LYNN (US) 2004-07-15 US disclosed
WO-2004026864-A1 HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC (US) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138230-A1 Heterocyclic substituted piperazines for the treatment of schizophrenia CNR1, DRD2, CNR2 MAPT 2926/4885HTT 1261/4885HSD17B10 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.